 The purpose of this quality improvement initiative is to develop and implement a physician pharmacist collaborative practice model, PPCPM, for the management of patients on buprenorphine slash naloxone for opioid use disorder, which minimizes provider burden, expands access to treatment, and enhances overall patient care. The PPCPM was piloted in an outpatient substance use disorder clinic with four hours per week dedicated to physician pharmacist collaborative medical appointments for a five-month trial period. Results showed that the PPCPM allowed for provision of a similar level of care regarding MUD and MH-related medication management while saving psychiatrist's time, and provided other enhancements to patient care through pharmacist intervention including more frequent identification and management of MUD adherence issues, referral for other services, and medication reconciliation interventions. This article was authored by Lindsay M. Mayew, PharmD, Matthew T. Haas, PharmD, BCPP, BCPS, Janelle M. LaRue, PharmD, BCPS, and others. We are article.tv, links in the description below.